Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Survival and failure types after radiation therapy of vulvar cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Individualized estimates of overall survival in radiation therapy plan optimization - A concept study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cancer of the corpus uteri

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background and purpose: Describe the survival rates and distribution of events on competing failure types in vulvar carcinoma after treatment with chemoradiation (CRT) or radiation (RT) alone.

Material and methods: We included patients with vulvar carcinoma treated with CRT or RT between 2009 and 2014. Survival was estimated using the Kaplan-Meier method. We performed a competing risk analysis and included five competing events: loco-regional failure (LRF), distant metastasis, LRF plus distant metastasis, and death without evidence of disease, with the remaining patients denoted alive without evidence of disease.

Results: 87 patients were treated. Progression free survival (PFS) and overall survival (OS) at 3 years were 40% and 57%, respectively. 41.3% of patients relapsed, most often loco-regionally. We saw significantly worse PFS and OS for patients older than 68 (p = 0.011/p = 0.010) and for patients treated with definitive RT (p = 0.004/p = 0.005). Competing risk analysis showed increased risk of LRF, and that death was most often related to vulvar cancer. Death without disease recurrence was less frequent, even in the elderly.

Conclusions: LRF was the most common event. PFS and OS were inferior for elderly patients and patients treated definitively. A better understanding of these differences may be used to define risk adapted treatment strategies.

Original languageEnglish
JournalClinical and Translational Radiation Oncologi
Volume5
Pages (from-to)20-27
Number of pages8
ISSN2405-6308
DOIs
Publication statusPublished - 2017

ID: 51905810